02.11.2026

To,

National Stock Exchange of India Limited
"Exchange Plaza",
Bandra-Kurla Complex,
Bandra (East) Mumbai 400 051

BSE Limited
Floor- 25, P J Tower,
Dalal Street,
Mumbai 400 001

SYMBOL:- EPIGRAL

Scrip Code: 543332

Dear Sirs,

Sub.: Investors Presentation on Un-Audited Financial Results – Q2 FY27
Ref.: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Investors Presentation on Un-Audited Financial Results – Q2 FY27.

The said Earnings Presentation is also available at www.epigral.com in the Investor Relations section.

This is for information and records.

Thanking you,

Yours faithfully,

For Epigral Limited

GAURANG GHANSHYAM TRIVEDI
Digitally signed by GAURANG GHANSHYAM TRIVEDI
Date: 2026-11-02 14:00+05:30

Gaurang Trivedi
Company Secretary & Compliance Officer
M. No. 22307

Epigral Limited
Epigral Tower, Behind Safal Profitaire, Corporate Road
Prahladnagar, Ahmedabad 380015, Gujarat, India.

T +91 79 2970 9600
E info@epigral.com
W epigral.com

CIN L24100GJ2007PLC051717

EPIGRAL

Epigral Limited

Investor Presentation – Q2FY2027



Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Epigral Limited (the "Company") solely for the information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company

Certain statements in this presentation concerning our future growth prospects are forward looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The Risk and uncertainties relating to the statements include, but are not limited to, risks and uncertainties regarding fiscal policy, competition, inflationary pressures and general economic conditions affecting demand / supply and price conditions in domestic and international markets. The company does not undertake to update any forward -looking statement that may be made from time to time by or on behalf of the company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. The Company does not make any promise to update/provide such presentation along with results to be declared in the coming years.

EPIGRAL

Q2FY27 Result update

Key Highlights

Q2FY27 Key Financial Highlights:

- YoY sales volume grew by 6%, despite the challenging and volatile market conditions
- Revenue grew by 28% to ₹ 752 Crore on account of volume growth and majorly due to improved realizations
- Derivatives & Specialty business contributed 57% of revenue vs 50% in Q2FY26
- EBITDA grew by 3% to ₹ 136 Crore vs ₹ 132 Crore. EBITDA margin was muted on account of high cost of raw materials and stood at 18%
- PAT grew by 26% to ₹ 64 Crore vs ₹ 51 Crore.

H1FY27 Key Financial Highlights:

- Revenue increased by 21% to ₹1,461 Crore, compared to ₹1,204 Crore, even after geopolitical tensions, volatile price movements, and off season for few of our products
- EBITDA grew by 7% to ₹ 315 Crore vs ₹ 296 Crore. EBITDA margin was maintained at 22%
- PAT rose by 25% to ₹ 164 Crore vs ₹ 131 Crore. PAT margin stood at 11%
- Net Debt/EBITDA stood at 0.9x as on 30th September 2026 vs 0.8x as on 30th September 2025

Key Highlights

H1FY27 Strategic Highlights:

- Epigral spent ₹ 88 Crore on capex in H1FY2027
- Epigral's board approved capex in below two projects, which are expected to commission by H2FY28
  - Epoxy Resin & Formulations plant with capacity of 1,25,000 TPA
  - Multi-Purpose Plant (MPP) downstream for Epichlorohydrin (ECH) and Chlorotoluene Value Chain
- Epigral has set up pilot plant for Epoxy Resin & Formulations and MPP to optimise manufacturing process, validate product quality and facilitate customer approvals ahead of commercial scale production
- Capex of enhancing CPVC Resin, ECH and Wind Solar Hybrid Power Plant capacity are in last lag of project and should be commissioned in a quarters time

CMD Message


"Despite a challenging operating environment in Q2FY27, we achieved revenue growth of 28%, driven by volume growth and improved realisations. Elevated raw material prices had its impact on EBITDA margins; however, our H1FY27 performance remained resilient, with revenue growth of 21% and an EBITDA margin of 22%. With the second half of the fiscal traditionally delivering stronger performance than the first, we maintain positive outlook for H2FY27."

"Fueled by India's robust demand growth, we are executing our expansion plans on schedule. The CPVC and ECH expansions are in their final stages with trial runs underway; both plants are expected to commission in a quarter's time. Meanwhile, our Epoxy Resin & Formulation and MPP projects are progressing as planned. The Revenue contribution from Derivatives & Specialty business stood at 57% and will expand further with these projects".


Epigral remains focused on strengthening its integrated manufacturing ecosystem, broadening its portfolio of high-value chemical products, and creating long-term value for all stakeholders"

- Mr. Maulik Patel, Chairman and Managing Director

Q2FY27 Financial Highlights




H1FY27 Financial Highlights



₹ Crore — Margin -%

**As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 212 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 131 Cr*

Key ratios as on 30th September 2026




**TTM EBIT, PAT and EBITDA are considered for above ratios*

#Capital employed in ROCE includes Capital Work in Progress

^PAT considered here for ROE for Q1FY26 is of Rs. 79 Cr (instead of Rs. 160 Cr), after reducing it by Rs. 81 Cr for benefit of reduction in Deferred tax liability, as the company shifted to new tax rate of 25.17% from FY2026

Revenue Transition towards Derivatives & Specialty Chemicals



EPIGRAL

Capex Plan

Capex Plan: Epoxy Resin and Multi Purpose Plant

Epoxy Resin & Formulations

Project Details

- Capacity: 1,25,000 TPA
- Location: Existing Complex, Dahej
- Expected commissioning: H2FY28

Rationale

- Growing demand in India, expected to grow at double digit percentage
- Strengthening integrated complex: Epichlorohydrin and Caustic Soda are among the key raw materials
- Catering to industries such as construction, renewables energy, automotive, electronics, infrastructure, marine, aerospace, industrial flooring, etc

Multi Purpose Plant (MPP)

Project Details

- Downstream of Epichlorohydrin and Chlorotoluenes Value Chain
- Location: Exiting Complex, Dahej
- Expected commissioning: H2FY28

Rationale

- Import substitute products
- Strengthening integrated complex: ECH and Chlorotoluenes Value Chain will be consumed as RM
- Catering to Agrochemical and Pharmaceuticals Intermediates and Water Treatment Chemicals
- Strengthening Epigral's position in Specialty Chemicals

Capex Plan: Enhancing CPVC and Epichlorohydrin

CPVC

Project Details

- Additional capacity – 75,000 TPA
- Total capacity after expansion – 1,50,000 TPA (World's largest plant by capacity)
- Expected commissioning – Q3FY27

Rationale

- Demand in India is expected to grow at ~ 12% - 13% CAGR
- Increasing Chlorine consumption in house, further strengthening integrated complex
- For CPVC, Epigral has established itself, for setting up plant, operating plant efficiently and having good market presence

Epichlorohydrin (ECH)

Project Details


- Additional capacity – 50,000 TPA
- Total capacity after expansion – 1,00,000 TPA (India's largest plant by capacity)
- Expected commissioning – Q3FY27

Rationale

- Demand in India is expected to grow at high double digit %
- Increasing captive consumption of Chlorine, Hydrogen and Caustic Soda, further strengthening integrated complex
- For ECH, Epigral has established itself, for setting up plant, operating plant efficiently and having good market presence both in India and globally

Capex Project Update as on 30th September 2026

Product	Capacity	Expected Commissioning Date
Wind Solar Hybrid Power Plant (Additional)	19.80 MW	Q3FY27
CPVC Resin (Additional)	75 KTPA	Q3FY27
Epichlorohydrin (Additional)	50 KTPA	Q3FY27
Epoxy Resin & Formulations	125 KTPA	H2FY28
Multi Purpose Plant	-	H2FY28



Income Statement

Particulars (₹ Crore)	Quarterly					Half Yearly		
	Q2FY27	Q2FY26	YoY %	Q1FY27	QoQ %	H1FY27	H1FY26	YoY %
Total Revenue	752	589	28%	709	6%	1,461	1,204	21%
Gross Profit	236	220	7%	278	-15%	513	472	9%
Gross Margin (%)	***32%***	***37%***		***39%***		***35%***	***40%***	
EBITDA	136	132	3%	179	-24%	315	296	7%
EBITDA Margin (%)	***18%***	***23%***		***25%***		***22%***	***25%***	
Depreciation	44	42	5%	43	3%	87	84	4%
Finance Cost	11	22	-51%	7	49%	18	45	-60%
PBT	87	70	24%	133	-35%	220	177	25%
PAT	64	51	26%	99	-35%	164	131*	25%
PAT Margin (%)	***9%***	***9%***		***14%***		***11%***	***11%***	
EPS (₹)	***14.9***	***11.9***		***23.0***		***37.9***	***30.3***	

**As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 212 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 131 Cr for H1FY26.*

EPIGRAL

Balance Sheet

Liabilities (₹ Crore)	FY25	FY26	H1FY27	Assets (₹ Cr)	FY25	FY26	H1FY27
Share Capital	43	43	43	Fixed Assets	2,302	2,568	2,559
Reserves & Surplus	1,860	2,178	2,320	Financial Assets	28	80	35
Long-Term Borrowings	449	334	391	Other Non-current Assets	46	31	25
Redeemable Preference Shares	0	0	0	Inventories	388	349	365
Other Non-current Liabilities	306	240	232	Trade Receivables	232	417	396
Short Term Borrowings	136	229	174	Cash & Bank Balances	22	5	1
Trade Payables	186	260	208	Investments	77	0	0
Other Current Liabilities	171	217	212	Loans & Advances	0	0	0
Short Term Provisions	0	4	4	Other Current Assets	56	56	202
Total	**3,151**	**3,505**	**3,584**	**Total**	**3,151**	**3,505**	**3,584**

EPIGRAL

Company Overview

Company Overview

- Founded: 2007
- Employees: 1,100 +
- Capacity: Chlor-Alkali# – 421 KTPA
  Derivatives# – 250 KTPA
- Certified: EcoVadis Silver Medal
- Manufacturing facility: Fully-integrated & automated complex


25%
5 Year Revenue CAGR (FY26)

17%
5 Year EBITDA CAGR (FY26)

0.9x
Net Debt to EBITDA (FY26)

16%
ROCE (FY26)

Revenue (₹ Crore)



 # Chlor-Alkali : Caustic Soda - 400 KTPA and Caustic Potash - 21 KTPA
Derivatives : CPVC Resin – 75 KTPA, Epichlorohydrin – 50 KTPA, Chlorotoluenes Value Chain – 15 KTPA, Chloromethanes - 50 KTPA and Hydrogen Peroxide - 60 KTPA

Our Journey

FY 2007

Epigral Ltd (MFL) incorporated

FY 2010

Commissioned 1st Plant
- **Caustic Soda – 119 KTPA**
- **CPP – 40 MW**

FY 2015

Increased capacity to
- **Caustic Soda – 167 KTPA**
- **CPP – 60 MW**

FY 2017

Commissioned
- **Caustic Potash – 21 KTPA**

Converted all Membrane to Zero Gap

FY 2020

Commissioned
- **Chloromethanes – 50 KTPA**

FY 2021

Commissioned
- **Hydrogen Peroxide – 60 KTPA**

Increased capacity to
- **Caustic Soda – 294 KTPA**
- **CPP 96 MW**

Awarded "**Responsible Care**" Certificate

FY 2023

Commissioned
- **Epichlorohydrin – 50 KTPA**
- **CPVC Resin – 30 KTPA**

Increased capacity to
Caustic Soda – 400 KTPA
CPP – 132 MW

FY 2024

Renamed company **from Meghmani Finechem to Epigral**

Commissioned
- **18.34 MW Green Hybrid Power Plant**

Inaugurated R&D Centre

FY 2025

Commissioned
- **CPVC Resin – 45 KTPA *(Total capacity stood at 75 KTPA)***
- ***CPVC Compound – 35 KTPA***
- ***Chlorotoluenes Value Chain***

Announced Capex
- **CPVC Resin – additional 75 KTPA**
- **Epichlorohydrin – additional 50 KTPA**

FY 2027

Announced Capex
- **Epoxy Resin & Formulations – 125 KTPA**
- **Multi Purpose Plant**

EPIGRAL

Our Values

TOGETHER

Teamwork
Passion
Relationships

CARING for

Quality Colleagues
EHS

AGILE

On time
OTIF
Faster

MAKE IT HAPPEN

Keep promises
Own the outcome

Together, in caring and agile manner, we make it happen

Chlor-Alkali

Caustic Soda (NaOH)

❖ Expected demand CAGR: ~ 8%


Alumina



Textile


Chemicals

- We are 4th largest producer in India
- Caustic Soda is basic raw material and caters to many industries. Major industries are alumina, textile, chemical, etc.
- Domestic demand for Caustic Soda is expected to increase to 5.0 million ton by FY2027
- Co-products are key raw material for our value added downstream products (CMS, H2O2, ECH and CPVC)

Caustic Potash (KOH)

❖ Expected Demand CAGR: ~ 8%


Agrochemicals


API

- We are 3rd largest producer in India
- Caustic Potash is majorly consumed in soap & detergent, agrochemical and pharmaceutical industry
- The India's capacity stands at 83 KTPA
- Co-products are key raw material for our value added downstream products (CMS, H2O2, ECH and CPVC)

Derivative Products

Chloromethanes (CMS)

❖ Expected demand CAGR: ~ 12%



Solvent in Pharma



PTFE Pipes



Refrigerant Gas

- We are 6th largest producer in India
- CMS plant produces 3 products, MDC, Chloroform and CTC. It is majorly drive by MDC
- The India's capacity stands at 677 KPTA
- CMS is used majorly in pharmaceutical, refrigerant, Tetrafluoroethylene (TFE), etc.

Hydrogen Peroxide (H2O2)

❖ Expected demand CAGR: ~ 10%



Paper & pulp



Textile



Chemicals

- We are 5th largest producer in India
- H2O2 demand will continue to grow driven by diverse industrial uses – paper & pulp, textiles, effluent treatment, chemicals, etc.
- The India's capacity stands at 429 KTPA

Derivatives & Specialty Chemicals

CPVC

❖ Expected demand CAGR: ~ 13%





Pipes and Fixtures

- Expanding – Will be world's largest manufacturer
- Key raw material for heat resistant pipes
- Growing demand of CPVC in India for Pipe and Fittings in residential and commercial properties
- Cater to both CPVC Resin and CPVC compound customer
- India is net importer of CPVC

Epichlorohydrin (ECH)

❖ Expected demand CAGR: ~ 15%



Wind mill



Automobile



Adhesives

- 1st company in India to produce sustainable bio based ECH
- Domestic alternative for 100% imported product
- Consuming Chlorine, Hydrogen and Caustic Soda – Strengthening integrated complex
- Catering to epoxy resin, pharmaceutical, water treatment chemicals and various other industries

Derivatives & Specialty Chemicals

Chlorotoluenes Value Chain

❖ Expected demand CAGR: Double digit %



Agrochemicals Intermediates




Pharmaceuticals Intermediates

- 1st company in India to commission this value chain
- Will serve Intermediates for manufacturing pharmaceutical and agrochemical active ingredients
- In 1st phase, ~ 10 to 12 set of products will be manufactured through following reactions – Chlorination, Photo Chlorination, Hydrolysis and Cyanation
- Chlorine will be consumed as raw material – strengthening integrated complex

Diversified and integrated portfolio

Fully Integrated Product Portfolio




- **High Value Products**
- **Import Substitution – Make in India**
- **Diversified End User Industries**
- **1st Manufacturer of ECH in India**

Diversifying Portfolio; De-Risking Business Model

EPIGRAL

Fully Integrated Complex



Competitive Strength

Well Invested Infrastructure

- State of the art manufacturing facility
- Strategic location with close connectivity to ports and raw material availability.
- Secured land for future growth of 5 to 7 years

Well established brand

- Epigral is a known brand in Indian chemical market
- Serving domestic customers for last 14 Yrs
- Pan India reach through a wide network of distributors

Focused on Efficiency

- Low cost operations as fully backward and forward integration
- Fully automated complex
- Continuous addition of value added products

Diversified Application Base

- Catering to more than 16 industries
- Revenue split is evened out among customer base
- End user market growing rapidly

Underpinned by a Technically Qualified Leadership Team

Catering to high growth industries

Increased market potential & higher growth exposure



The addressable market for Epigral is growing ~10-13% in the next 5 years

Key Customers






































Diversified Product Portfolio


Manufacturing Plant Capacity (KTPA)



*Expected Commissioning, * Expected Commissioning date*

Transitioning towards Derivatives & Specialty Chemicals





Revenue from the derivatives and specialty segment to be ~ 70% by FY28E

Derivatives & Specialty – CPVC Resin, Epichlorohydrin, Chloromethanes and Hydrogen Peroxide
Chlor-Alkali – Caustic Soda and Caustic Potash

Research & Development Centre

- A step towards **strengthening presence in Specialty chemicals**

- **Location Changodar, Ahmedabad**

- R&D center will be used for creating further molecules for Chlorotoluene and other new molecules, which will be intermediates for pharmaceutical and agrochemical active ingredients

- **Our reaction expertise**
  - Electrolysis
  - Hydrogenation
  - Ring Chlorination
  - Hydrolysis
  - Cyanation
  - Chlorination
  - Hydro Chlorination
  - Photo Chlorination
  - Diazotization
  - Oxidation



Focused on ESG



ENVIRONMENT

- Focused on using **best technology** to manage critical resources, to moderate the consumption of energy and natural resources and drive operations efficiently
- Focus is to manufacture more from less, basis for environment responsibility
- **Entered in JV to set up 38.14 MW Wind-Solar Hybrid Power Plant for internal consumption**
- Intend is to minimize effluents discharge while moderating water consumption
- **First company to produce sustainable bio-based Epichlorohydrin**
- **Safety protocols imbibing in the culture** of the company and timely management review safety systems with quantified leading and lagging indicators



SOCIAL RESPONSIBILITY

- **Employees** – Investment in culture of excellence, timely training, scope for growth, talent investment, extensive safety provisions and supporting financially and mentally in difficult times
- **Community** – Engaged community around manufacturing plant. Supporting them in difficult times. Deeply rooted CSR in the area of education, health & family welfare, sustainable livelihood, infrastructure and other social activities
- **Customers and vendors** – Strong and long relation with customers and vendors. Over a period built on ecosystem of vendors and primary customers

GOVERNANCE

- Qualified and experienced board driving strategic decisions, ethics and values
- Focus on managing the business in transparent manner with all stakeholders
- All the strategic decisions are taken considering interest of minority shareholders
- Reputed statutory auditor - SRBC & Co LLP
- Timely disclosure of material announcements

Experienced and qualified board

Mr. Maulik Patel
Chairman & Managing Director

He has 16 years of experience in the chemical industry. He has played a key role in growth of Epigral. He actively looks after operations, projects expansion, identifying new products, building a team, etc. He has done MSc in chemical engineering and MBA.

Mr. Kaushal Soparkar
Executive Director

He has 15 years of experience in the chemical industry. He actively looks after finance, IT and Human Resource. He has done MS in Engineering Management.

Mr. Ankit Patel
Non-Executive, Non-Independent Director

He has 14 years of experience in the chemical industry. He is Chairman & Managing Director at Meghmani Organics Limited. He has done MS in Engineering Management and MBA.

Mr. Karana Patel
Non-Executive, Non-Independent Director

He has 14 years of experience in the chemical industry. He is Executive Director at Meghmani Organics Limited and looks after the Agrochemicals division. He has done diploma and B.E. in chemicals.

Mr. Darshan Patel
Non-Executive, Non-Independent Director

He has 13 years of experience in the chemical industry. He is Executive Director at Meghmani Organics Ltd and looks after the pigment division. He has done MS in Engineering Management and MBA.

Mr. Manu Patel
Non-Executive, Independent Director

He is a Chartered Accountant. He was associated with Zydus Group for 35 years and was heading Finance & Taxation. He has expertise in the field of Forex, Treasury and Credit Management.

Mr. Sanjay Asher
Non-Executive, Independent Director

He is a senior partner with M/s Crawford Bayley & Co and practicing advocate since 1991. He specializes in the field of M&A, JVs, Private Equity and Capital Markets. He is a CA and LLB graduate.

Mr. Kanu Patel
Non-Executive, Independent Director

He is CMD at Voltamp Transformers Ltd and has been associated with the company for more than 41 years. He has expertise in finance, marketing, commercial matters and strategic planning. He is a member of ICAI and ICSI.

Mr. Raju Swamy
Non-Executive, Independent Director

He is into management consulting in family business for over 35 years. He has expertise in marketing, projects and HR. He has done MBA from IIM Calcutta,

Mrs. Priyanka Chopra
Non-Executive, Independent Director

She is CEO at IIMA Ventures. She has expertise in investing, advising and engaging with early stage companies. She holds MBA from The Wharton School and M.S. in Electrical Engineering from the Georgia Institute of Technology.

- **Board comprises of accomplished and knowledgeable directors, contributing diverse expertise and perspective to our collective decision making**
- **50% of the board comprises of Independent Directors**
- **Our 5 board committees are chaired by an Independent Director**

Growth Strategy

Forward & Backward Integration:

- Scale up capacities in existing products
- New value added products in existing value chains
- Improved market position

Opportunities in high growth sectors:

- Explore opportunities in various sectors
- Increase presence & improve market share
- Entering into products which are fully imported

New Value Chains:

- Expand chemistry expertise to enter new value chains (specialty chemicals)
- Addition of new reaction capabilities

Achieving economies of scale:


- Optimising existing complex
- Achieving efficiency operations to become a low cost producer

EPIGRAL


Historical numbers

Financial Performance – P&L


Revenue (₹ Crore)



EBITDA (₹ Crore and %)




PAT (₹ Crore and %)



Margin -%

**As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 333 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 252 Cr for FY2026.*

Balance Sheet Ratios



#Capital employed in ROCE includes Capital Work in Progress

Historic Income Statement

Particulars (₹ Cr)	FY2022	FY2023	FY2024	FY2025	FY2026
Total Revenue	1,555	2,196	1,936	2,565	2,542
Gross Profit	716	951	763	1,067	941
Gross Margin (%)	***46%***	***43%***	***40%***	***42%***	***37%***
EBITDA	509	689	481	711	567
EBITDA Margin (%)	***33%***	***31%***	***25%***	***28%***	***22%***
Depreciation	86	109	124	133	168
Finance Cost	44	66	73	53	72
PBT	383	523	291	540	342
PAT	***253***	***353***	***196***	***357***	***333****
PAT Margin (%)	***16%***	***16%***	***10%***	***14%***	***13%***
EPS (₹)	***60.8***	***85.0***	***47.1***	***84.4***	***77.1***

**As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 333 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 252 Cr for FY2026.*

EPIGRAL

Balance Sheet

Liabilities (₹ Crore)	FY24	FY25	FY26	Assets (₹ Cr)	FY24	FY25	FY26
Share Capital	42	43	43	Fixed Assets	2,249	2,302	2,568
Reserves & Surplus	1,213	1,860	2,178	Financial Assets	29	28	80
Long-Term Borrowings	492	449	334	Other Non-current Assets	14	46	31
Redeemable Pref. Shares	55	0	0	Inventories	263	388	349
Other Non-current Liabilities	214	306	243	Trade Receivables	179	232	417
Short Term Borrowings	416	136	229	Cash & Bank Balances	7	22	5
Trade Payables	184	186	260	Investments	0	77	0
Other Current Liabilities	179	171	218	Loans & Advances	0	0	0
Short Term Provisions	0	0	0	Other Current Assets	53	56	56
Total	**2,794**	**3,151**	**3,505**	**Total**	**2,794**	**3,151**	**3,505**

EPIGRAL

Enhance to Exceed

Established in 2007, Epigral Limited is a premier integrated chemical manufacturer in India, operating a highly automated and infrastructure-rich manufacturing complex at Dahej, Gujarat. As a pioneer in the domestic chemical industry, the company commissioned India's first Epichlorohydrin (ECH) plant, established the country's first Chlorotoluenes Value Chain facility, and operates India's largest CPVC resin production capacity.

The company's portfolio includes key products such as Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, CPVC, Epichlorohydrin, and Chlorotoluenes Value Chain. With its planned entry into Epoxy Resin & Formulations and setting up MPP, Epigral is further strengthening its presence in advanced materials and specialty chemicals aligned with growing domestic demand.

Driven by operational excellence and sustainable manufacturing, Epigral continues to focus on high-value specialty chemical expansion through its integrated manufacturing capabilities and dedicated R&D centre in Ahmedabad, creating long-term value for customers, partners, and stakeholders.

For further information

Please log on to website: www.epigral.com
Epigral Corporate Film: Video

Corporate Office

Epigral Tower, B/h Safal Profitaire, Corporate Road,
Prahladnagar, Ahmedabad 380015,
Gujarat, India

Manufacturing Site

CH/1 and CH/2, GIDC Industrial Estate, Dahej,
Tal. Vagra, Dist. Bharuch – 392130,
Gujarat, India